Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08, Zacks reports. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company's revenue for the quarter was up .0% compared to the same quarter last year.
Viridian Therapeutics Trading Down 1.9 %
VRDN traded down $0.24 during trading on Friday, reaching $12.54. The company had a trading volume of 655,726 shares, compared to its average volume of 1,195,808. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -2.91 and a beta of 0.57. The firm's 50-day simple moving average is $13.71 and its 200 day simple moving average is $17.53.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on VRDN. Royal Bank of Canada reduced their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday. Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday. The Goldman Sachs Group lowered their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday. JMP Securities cut their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday. Finally, HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.18.
Check Out Our Latest Research Report on VRDN
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
